Company intelligence / Profile preview

Yu Shan

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Yushan Oncology was a clinical-stage biopharmaceutical company focused on developing novel oncology therapies targeting epigenetic regulators. The company's lead program, YS-101 (now NUV-868), is a highly selective BET inhibitor designed to treat various advanced solid tumors. In June 2021, Yushan Oncology was acquired by Nuvation Bio, which integrated Yushan's pipeline into its own oncology portfolio. The acquisition aimed to leverage Yushan's expertise in small molecule drug discovery to expand Nuvation's reach in the epigenetic space. The lead asset is currently being evaluated in clinical trials for its potential to treat cancers with high unmet medical needs, such as prostate and pancreatic cancer.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Yu Shan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yu Shan.

Explore the full profile